RxSight (RXST) Non-Current Deferred Tax Liability (2022 - 2023)
RxSight's (RXST) quarterly Non-Current Deferred Tax Liability came in at $646000.0 in Q4 2023, down 44.45% YoY from $1.2 million in Q4 2022, and down 44.45% on a QoQ basis from $1.2 million in Q4 2022.
RxSight (RXST) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
RxSight (RXST) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $646000.0 in Q4 2023.
- Quarterly Non-Current Deferred Tax Liability fell 44.45% year-over-year to $646000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $646000.0 (down 44.45% YoY) and the FY2023 annual result came in at $646000.0, down 44.45% from the prior year.
- Non-Current Deferred Tax Liability slipped to $646000.0 in Q4 2023, from $1.2 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.2 million in Q4 2022 to a low of $646000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.51 Bn | 194.91 Bn | 7.27 Bn |
| 2 | Stryker | 129.96 Bn | 126.48 Bn | 4.50 Bn |
| 3 | Medtronic | 120.18 Bn | 110.96 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.28 Bn | 73.74 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.75 Bn | 48.50 Bn | 1.35 Bn |
| 6 | Dexcom | 34.67 Bn | 32.73 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.23 Bn | 32.12 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.14 Bn | 4.55 Bn |
| 9 | Steris | 23.30 Bn | 22.82 Bn | 684.20 Mn |
| 10 | RxSight | 253.72 Mn | -150.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 646,000.00 |
| Dec 31, 2023 | 646,000.00 |
| Dec 31, 2022 | 1.16 Mn |
| Dec 31, 2022 | 1.16 Mn |